



DEPARTMENT OF COMMERCE UNITED STAT Patent and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS Address:

Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO.

09/495,947

02/02/00

COLEMAN

T

05270001AA

EXAMINER

HM12/0328

Whitham Curtis & Whitham Reston International Center 11800 Sunrise Valley Drive Suite 900 Reston VA 20191

DRABIK.C

ART UNIT

PAPER NUMBER

1633

DATE MAILED:

03/28/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	•	Application No.	Applicant(s)
•		09/495,947	COLEMAN ET AL.
	Office Action Summary	Examiner	Art Unit
		Christopher Drabik	1633
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status			
1)	Responsive to communication(s) filed on	·	
2a)	This action is FINAL . 2b) TI	his action is non-final.	
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims			
4) Claim(s) 1-23 is/are pending in the application.			
4a) Of the above claim(s) is/are withdrawn from consideration.			
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claims 1-23 are subject to restriction and/or election requirement.			
Application Papers			
9) The specification is objected to by the Examiner.			
10)☐ The drawing(s) filed on is/are objected to by the Examiner.			
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved.			
12) The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. § 119			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) All b) Some * c) None of:			
1. Certified copies of the priority documents have been received.			
2. Certified copies of the priority documents have been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.			
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).			
Attachment(s)			
16) No	ntice of References Cited (PTO-892) ntice of Draftsperson's Patent Drawing Review (PTO-948) formation Disclosure Statement(s) (PTO-1449) Paper No	19) Notice of Inform	nary (PTO-413) Paper No(s) nal Patent Application (PTO-152)

Election/Restrictions

The Restriction requirement mailed on 2 / 28 / 01 is vacated.

This application contains claims directed to the following patentably distinct species of the claimed invention: Wherein the first hapten is from single stranded DNA viruses, double stranded DNA viruses, single stranded RNA viruses, intracellular parasites, fungi, bacteria or cancer, wherein the second hapten is from single stranded DNA viruses, double stranded DNA viruses, single stranded RNA viruses, intracellular parasites, fungi, bacteria or cancer, wherein the nucleic acid is from the group 1,2 or 3 as designated in the specification.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-23 are generic.

Applicant is required to choose one first hapten, one second hapten and one group of nucleic acids.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Application/Control Number: 09/495,947

Art Unit: 1633

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher Drabik whose telephone number is 703-605-1156. The examiner can normally be reached on Monday-Friday from 9am to 5pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

Application/Control Number: 09/495,947

Art Unit: 1633

supervisor, Deborah Clark, can be reached on 703-305-4051. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4242.

Inquiries of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1234. Questions regarding review of formality issues may be directed to Kim Davis, the patent analyst assisting in this application. She may be reached at 703-305-3015.

DEBORAH J. R. CLARK ERVISORY PATENT FYAMILIE

TECHNOLOGY CENTER 1800